{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T13:01:37Z","timestamp":1789822897125,"version":"4.0.1"},"reference-count":56,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T00:00:00Z","timestamp":1722988800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCDD"],"abstract":"<jats:p>Pregnancy entails notable physiological alterations and hormonal fluctuations that affect the well-being of both the fetus and the mother. Cardiovascular events and arrhythmias are a major concern during pregnancy, especially in women with comorbidities or a history of arrhythmias. This paper provides an overview of the prevalence, therapies, and prognoses of different types of arrhythmias during pregnancy. The administration of antiarrhythmic drugs (AADs) during pregnancy demands careful consideration because of their possible effect on the mother and fetus. AADs can cross the placenta or be present in breast milk, potentially leading to adverse effects such as teratogenicity, growth restriction, or premature birth. The safety profiles of different classes of AADs are discussed. Individualized treatment approaches and close monitoring of pregnant women prescribed AADs are essential to ensure optimal maternal and fetal outcomes.<\/jats:p>","DOI":"10.3390\/jcdd11080243","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T07:01:25Z","timestamp":1723100485000},"page":"243","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Antiarrhythmic Drug Use in Pregnancy: Considerations and Safety Profiles"],"prefix":"10.3390","volume":"11","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9480-1209","authenticated-orcid":false,"given":"Marco Valerio","family":"Mariani","sequence":"first","affiliation":[{"name":"Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-4081","authenticated-orcid":false,"given":"Nicola","family":"Pierucci","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"},{"name":"Texas Cardiac Arrhythmia Institute, St. David\u2019s Medical Center, Austin, TX 78705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7548-4685","authenticated-orcid":false,"given":"Vincenzo Mirco","family":"La Fazia","sequence":"additional","affiliation":[{"name":"Texas Cardiac Arrhythmia Institute, St. David\u2019s Medical Center, Austin, TX 78705, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pietro","family":"Cipollone","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9122-9534","authenticated-orcid":false,"given":"Marco","family":"Micillo","sequence":"additional","affiliation":[{"name":"Cardiology Department, S. Anna University Hospital, 44122 Ferrara, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"D\u2019Amato","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1488-7015","authenticated-orcid":false,"given":"Francesca","family":"Fanisio","sequence":"additional","affiliation":[{"name":"Division of Cardiology, Policlinico Casilino, 00169 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7440-1793","authenticated-orcid":false,"given":"Giuseppe","family":"Ammirati","sequence":"additional","affiliation":[{"name":"Department of Advanced Biomedical Sciences, University of Naples Federico II, 80138 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nethuja","family":"Salagundla","sequence":"additional","affiliation":[{"name":"Texas Health Arlington Memorial Hospital, Dallas, TX 76012, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Lavalle","sequence":"additional","affiliation":[{"name":"Department of Clinical Internal Anesthesiologic and Cardiovascular Sciences, Sapienza University of Rome, 00161 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0511-2621","authenticated-orcid":false,"given":"Marco Alfonso","family":"Perrone","sequence":"additional","affiliation":[{"name":"Division of Cardiology and CardioLab, Department of Clinical Sciences and Translational Medicine, University of Rome Tor Vergata, 00133 Rome, Italy"},{"name":"Clinical Pathways and Epidemiology Unit, Bambino Ges\u00f9 Children\u2019s Hospital IRCCS, 00165 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,8,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1161\/CIRCULATIONAHA.116.026681","article-title":"Burden of Arrhythmia in Pregnancy","volume":"135","author":"Vaidya","year":"2017","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.jacc.2016.05.048","article-title":"High-Risk Cardiac Disease in Pregnancy","volume":"68","author":"Elkayam","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/hrt.2006.098822","article-title":"Managing palpitations and arrhythmias during pregnancy","volume":"84","author":"Adamson","year":"2008","journal-title":"Postgrad. Med. J."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1093\/eurheartj\/ehv316","article-title":"2015 European Society of Cardiology Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death summarized by co-chairs","volume":"36","author":"Priori","year":"2015","journal-title":"Eur. Heart J."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Hudson, R.E., Metz, T.D., Ward, R.M., McKnite, A.M., Enioutina, E.Y., Sherwin, C.M., Watt, K.M., and Job, K.M. (2023). Drug exposure during pregnancy: Current understanding and approaches to measure maternal-fetal drug exposure. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1111601"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1016\/S0002-9149(03)00339-4","article-title":"Cardiac risk in pregnant women with rheumatic mitral stenosis","volume":"91","author":"Silversides","year":"2003","journal-title":"Am. J. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3165","DOI":"10.1093\/eurheartj\/ehy340","article-title":"2018 ESC Guidelines for the Management of Cardiovascular Diseases during Pregnancy: The Task Force for the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)","volume":"39","author":"Bauersachs","year":"2018","journal-title":"Eur. Heart J."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Tamirisa, K.P., Dye, C., Bond, R.M., Hollier, L.M., Marinescu, K., Vaseghi, M., Russo, A.M., Gulati, M., and Volgman, A.S. (2022). Arrhythmias and Heart Failure in Pregnancy: A Dialogue on Multidisciplinary Collaboration. J. Cardiovasc. Dev. Dis., 9.","DOI":"10.3390\/jcdd9070199"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Francisco-Pascual, J., Vila, N.M., Santos-Ortega, A., and Rivas-G\u00e1ndara, N. (2024). Tachyarrhythmias in congenital heart disease. Front. Cardiovasc. Med., 11.","DOI":"10.3389\/fcvm.2024.1395210"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1694","DOI":"10.1016\/j.amjcard.2017.02.003","article-title":"National Trends and In-Hospital Outcomes in Pregnant Women with Heart Disease in the United States","volume":"119","author":"Lima","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1161\/CIRCULATIONAHA.116.025064","article-title":"Outcomes Associated with Paroxysmal Supraventricular Tachycardia during Pregnancy","volume":"135","author":"Chang","year":"2017","journal-title":"Circulation"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1093\/eurheartj\/ehr218","article-title":"ESC Guidelines on the management of cardiovascular diseases during pregnancy: The Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC)","volume":"32","author":"Lundqvist","year":"2011","journal-title":"Eur. Heart J."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/1715163516641136","article-title":"Drug-induced QT interval prolongation and torsades de pointes","volume":"149","author":"Tisdale","year":"2016","journal-title":"Can. Pharm. J."},{"key":"ref_14","unstructured":"(2024, February 14). Available online: https:\/\/www.govinfo.gov\/content\/pkg\/FR-2014-12-04\/pdf\/2014-28241.pdf."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"e175","DOI":"10.1016\/j.hrthm.2023.05.017","article-title":"2023 HRS expert consensus statement on the management of arrhythmias during pregnancy","volume":"20","author":"Joglar","year":"2023","journal-title":"Heart Rhythm."},{"key":"ref_16","unstructured":"Briggs, G.G., Towers, C.V., and Forinash, A.B. (2023, March 28). Briggs Drugs in PREGNANCY and Lactation: A Reference Guide to Fetal and Neonatal Risk: 1461. Available online: https:\/\/www.wolterskluwer.com\/en\/solutions\/ovid\/briggs-drugs-in-pregnancy-and-lactation-a-reference-guide-to-fetal-and-neonatal-risk-730."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/j.jacc.2018.10.075","article-title":"Use of medication for cardiovascular disease during pregnancy","volume":"73","author":"Halpern","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1161\/CIRCULATIONAHA.114.009029","article-title":"Cardiovascular Physiology of Pregnancy","volume":"130","author":"Sanghavi","year":"2014","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"328","DOI":"10.2165\/00003088-199733050-00002","article-title":"Pharmacokinetic changes during pregnancy and their clinical relevance","volume":"33","author":"Loebstein","year":"1997","journal-title":"Clin. Pharmacokinet."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/BF00609896","article-title":"Pharmacokinetics of sotalol during pregnancy","volume":"24","author":"Leahey","year":"1983","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/BF00556896","article-title":"Pharmacokinetics of propranolol during pregnancy","volume":"27","author":"Kinney","year":"1984","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"S745","DOI":"10.1016\/j.ajog.2017.11.577","article-title":"Pathophysiology of placental-derived fetal growth restriction","volume":"218","author":"Burton","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1038\/sj.clpt.6100377","article-title":"Pharmacokinetic Studies in Pregnant Women","volume":"83","author":"Anger","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1053\/j.semperi.2015.08.003","article-title":"Pharmacokinetics of drugs in pregnancy","volume":"39","author":"Feghali","year":"2015","journal-title":"Semin. Perinatol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.ajog.2004.08.030","article-title":"Temporal changes in drug metabolism (CYP1A2, CYP2D6 and CYP3A Activity) during pregnancy","volume":"192","author":"Tracy","year":"2005","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/ki.1980.124","article-title":"Renal hemodynamics and tubular function in normal human pregnancy","volume":"18","author":"Davison","year":"1980","journal-title":"Kidney Int."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1093\/europace\/euy067","article-title":"Sex differences in cardiac arrhythmia: A consensus document of the European Heart Rhythm Association, endorsed by the Heart Rhythm Society and Asia Pacific Heart Rhythm Society","volume":"20","author":"Linde","year":"2018","journal-title":"Europace"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Mariani, M.V., Pierucci, N., Fanisio, F., Laviola, D., Silvetti, G., Piro, A., La Fazia, V.M., Chimenti, C., Rebecchi, M., and Drago, F. (2024). Inherited Arrhythmias in the Pediatric Population: An Updated Overview. Medicina, 60.","DOI":"10.3390\/medicina60010094"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1093\/cvr\/27.1.54","article-title":"Cardiac electrophysiology and pharmacology of adenosine: Basic and clinical aspects","volume":"27","author":"Pelleg","year":"1993","journal-title":"Cardiovasc. Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/s00399-021-00759-2","article-title":"Antiarrhythmic drugs\u2014Safety and efficacy during pregnancy","volume":"32","author":"Fischer","year":"2021","journal-title":"Herzschrittmacherther. Elektrophysiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/0002-9149(92)90367-8","article-title":"Comparison of intravenous dosing regimens for maintaining steady-state procainamide levels during programmed ventricular stimulation","volume":"70","author":"Brautigam","year":"1992","journal-title":"Am. J. Cardiol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"487","DOI":"10.7326\/0003-4819-98-4-487","article-title":"Antiarrhythmic Drug Therapy during Pregnancy","volume":"98","author":"Rotmensch","year":"1983","journal-title":"Ann. Intern. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1007\/BF03005448","article-title":"The direct effects of circulating lidocaine on uterine blood flow and foetal well-being in the pregnant ewe","volume":"24","author":"Biehl","year":"1977","journal-title":"Can. J. Anaesth."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/0002-9378(74)90663-2","article-title":"Effects of lidocaine on heart rate, blood pressure, and electrocorticogram in fetal sheep","volume":"118","author":"Teramo","year":"1974","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0002-9378(87)80191-6","article-title":"Mexiletine use in pregnancy and lactation","volume":"157","author":"Lownes","year":"1987","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1177\/106002809402800907","article-title":"Flecainide distribution, transplacental passage, and accumulation in the amniotic fluid during the third trimester of pregnancy","volume":"28","author":"Bourget","year":"1994","journal-title":"Ann. Pharmacother."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1345\/aph.1C487","article-title":"Neonatal flecainide toxicity following supraventricular tachycardia treatment","volume":"37","author":"Hall","year":"2003","journal-title":"Ann. Pharmacother."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1111\/j.1365-2125.1991.tb03945.x","article-title":"Transfer of propafenone and 5-OH-propafenone to foetal plasma and maternal milk [letter]","volume":"32","author":"Libardoni","year":"1991","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e20160731","DOI":"10.1542\/peds.2016-0731","article-title":"Late Pregnancy \u03b2 Blocker Exposure and Risks of Neonatal Hypoglycemia and Bradycardia","volume":"138","author":"Bateman","year":"2016","journal-title":"Pediatrics"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1001\/jamainternmed.2017.0608","article-title":"\u03b2-Blocker Exposure in Pregnancy and Risk of Fetal Cardiac Anomalies","volume":"177","author":"Duan","year":"2017","journal-title":"JAMA Intern. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/BF00442136","article-title":"Effects of propranolol during pregnancy and development of rats","volume":"143","author":"Schoenfeld","year":"1985","journal-title":"Eur. J. Pediatr."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1016\/S0002-9149(97)00163-X","article-title":"Effect of atenolol on birth weight","volume":"79","author":"Lip","year":"1997","journal-title":"Am. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2165\/00003088-198409020-00002","article-title":"Clinical pharmacokinetics of amiodarone","volume":"9","author":"Latini","year":"1984","journal-title":"Clin. Pharmacokinet."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/bdrb.21162","article-title":"The Effect of Dofetilide on the Heart Rate of GD11 and GD13 Rat Embryos, in vivo, Using Ultrasound","volume":"104","author":"Ritchie","year":"2015","journal-title":"Birth Defects Res. Part B Dev. Reprod. Toxicol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/bdrb.21050","article-title":"The Teratogenic effect of dofetilide during rat limb development and association with drug-induced bradycardia and hypoxia in the embryo","volume":"98","author":"Ritchie","year":"2013","journal-title":"Birth Defects Res. Part B Dev. Reprod. Toxicol."},{"key":"ref_46","unstructured":"(1996). Developmental toxicity of ibutilide fumarate in rats after oral administration. Teratology, 5, 157\u2013164."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/S0002-9378(96)70307-1","article-title":"The safety of calcium channel blockers in human pregnancy: A prospective, multicenter cohort study","volume":"174","author":"Magee","year":"1996","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"103","DOI":"10.2535\/ofaj1936.52.2-3_103","article-title":"Effects of diltiazem hydrochloride on embryonic development: Species differences in the susceptibility and stage specificity in mice, rats, and rabbits","volume":"52","author":"Ariyuki","year":"1975","journal-title":"Okajimas Folia Anat. Jpn."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/0735-6757(92)90181-V","article-title":"Adenosine use in pregnancy: Lack of effect on fetal heart rate","volume":"10","author":"Leffler","year":"1992","journal-title":"Am. J. Emerg. Med."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0735-6757(00)90033-0","article-title":"Fetal bradycardia after IV adenosine for maternal PSVT","volume":"18","author":"Dunn","year":"2000","journal-title":"Am. J. Emerg. Med."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1471-0528.1978.tb14929.x","article-title":"Transfer of digoxin across the placenta and into breast milk","volume":"85","author":"Chan","year":"1978","journal-title":"Br. J. Obstet. Gynaecol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1055\/s-0036-1586241","article-title":"Digoxin Therapy of Fetal Superior Ventricular Tachycardia: Are Digoxin Serum Levels Reliable?","volume":"6","author":"Monsivais","year":"2016","journal-title":"Am. J. Perinatol. Rep."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"167.e1","DOI":"10.1016\/j.ajog.2018.09.035","article-title":"Addressing maternal mortality: The pregnant cardiac patient","volume":"220","author":"Wolfe","year":"2018","journal-title":"Am. J. Obstet. Gynecol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1097\/AOG.0000000000002114","article-title":"Pregnancy-Related Mortality in the United States, 2011\u20132013","volume":"130","author":"Creanga","year":"2017","journal-title":"Obstet. Gynecol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e561","DOI":"10.1542\/neo.20-10-e561","article-title":"Maternal Mortality in the United States: Updates on Trends, Causes, and Solutions","volume":"20","author":"Collier","year":"2019","journal-title":"NeoReviews"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"379.e1","DOI":"10.1016\/j.ajog.2015.05.008","article-title":"Pregnancy-related cardiovascular deaths in California: Beyond peripartum cardiomyopathy","volume":"213","author":"Hameed","year":"2015","journal-title":"Am. J. Obstet. Gynecol."}],"container-title":["Journal of Cardiovascular Development and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/8\/243\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:31:42Z","timestamp":1760110302000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2308-3425\/11\/8\/243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,7]]},"references-count":56,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2024,8]]}},"alternative-id":["jcdd11080243"],"URL":"https:\/\/doi.org\/10.3390\/jcdd11080243","relation":{},"ISSN":["2308-3425"],"issn-type":[{"value":"2308-3425","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,7]]}}}